Literature DB >> 12691483

Antipsychotic drug-induced movement disorders.

Pierre J Blanchet1.   

Abstract

Very early in the process of diagnosing abnormal involuntary movement (AIM) disorders, one can be rewarded by keeping a high index of suspicion for possible drug-induced causes, not only through a complete list of current medications, but also identification of the drugs the patient used to take and other possible offending medications that might be available from family members and other sources. Among drug-induced movement disorders, antipsychotic drugs and other dopamine receptor blocking agents occupy a central place. Their various acute and tardive motor complications provide the template of this short review. Movement disorders caused by antidepressants, lithium, antiemetics, antiparkinsonian agents, anticonvulsants, calcium channel blockers, sympathomimetics and others are only briefly covered in table form.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12691483     DOI: 10.1017/s0317167100003309

Source DB:  PubMed          Journal:  Can J Neurol Sci        ISSN: 0317-1671            Impact factor:   2.104


  14 in total

Review 1.  Movement disorders of the mouth: a review of the common phenomenologies.

Authors:  C M Ghadery; L V Kalia; B S Connolly
Journal:  J Neurol       Date:  2022-07-29       Impact factor: 6.682

2.  Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data.

Authors:  Kazunari Yoshida; Robert R Bies; Takefumi Suzuki; Gary Remington; Bruce G Pollock; Yuya Mizuno; Masaru Mimura; Hiroyuki Uchida
Journal:  Schizophr Res       Date:  2014-02-01       Impact factor: 4.939

3.  Genome-wide association study of antipsychotic-induced parkinsonism severity among schizophrenia patients.

Authors:  Ana Alkelai; Lior Greenbaum; Amihai Rigbi; Kyra Kanyas; Bernard Lerer
Journal:  Psychopharmacology (Berl)       Date:  2009-08-13       Impact factor: 4.530

4.  Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model.

Authors:  Souha Mahmoudi; Daniel Lévesque; Pierre J Blanchet
Journal:  Mov Disord       Date:  2014-05-16       Impact factor: 10.338

5.  Acute dystonic reaction as medical emergency: a report of two cases.

Authors:  Ao Oyewole; Ao Adelufosi; O Abayomi
Journal:  Ann Med Health Sci Res       Date:  2013-07

Review 6.  Relevance of animal models to human tardive dyskinesia.

Authors:  Pierre J Blanchet; Marie-Thérèse Parent; Pierre H Rompré; Daniel Lévesque
Journal:  Behav Brain Funct       Date:  2012-03-09       Impact factor: 3.759

Review 7.  Pharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genes.

Authors:  Lior Greenbaum; Bernard Lerer
Journal:  Front Neurol       Date:  2015-02-20       Impact factor: 4.003

8.  Phencyclidine Induced Oculogyric Crisis Responding Well to Conventional Treatment.

Authors:  Hassan Tahir; Vistasp Daruwalla
Journal:  Case Rep Emerg Med       Date:  2015-05-26

Review 9.  Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders.

Authors:  Yahya E Choonara; Viness Pillay; Lisa C Du Toit; Girish Modi; Dinesh Naidoo; Valence M K Ndesendo; Sibongile R Sibambo
Journal:  Int J Mol Sci       Date:  2009-06-03       Impact factor: 6.208

10.  Do tardive dyskinesia and L-dopa induced dyskinesia share common genetic risk factors? An exploratory study.

Authors:  Lior Greenbaum; Stefano Goldwurm; Polina Zozulinsky; Tzuri Lifschytz; Oren S Cohen; Gilad Yahalom; Roberto Cilia; Silvana Tesei; Rosanna Asselta; Rivka Inzelberg; Yoav Kohn; Sharon Hassin-Baer; Bernard Lerer
Journal:  J Mol Neurosci       Date:  2013-05-12       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.